These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22690082)

  • 81. Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.
    Wang L; Chen YZ; Shi D; Shi XY; Zou Z; Zhao JH
    Drugs R D; 2011 Dec; 11(4):317-26. PubMed ID: 22133387
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer.
    Windarti I; Harahap WA; Nindrea RD; Yerizel E; Rustamadji P
    Open Access Maced J Med Sci; 2019 Nov; 7(21):3716-3720. PubMed ID: 32010404
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Biomarkers in Colorectal Cancer: Current Research and Future Prospects.
    Ogunwobi OO; Mahmood F; Akingboye A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726923
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.
    Koulis C; Yap R; Engel R; Jardé T; Wilkins S; Solon G; Shapiro JD; Abud H; McMurrick P
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231042
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.
    Lima ZS; Ghadamzadeh M; Arashloo FT; Amjad G; Ebadi MR; Younesi L
    J Hematol Oncol; 2019 Apr; 12(1):38. PubMed ID: 30975222
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
    Smyth LM; Monson KR; Jhaveri K; Drilon A; Li BT; Abida W; Iyer G; Gerecitano JF; Gounder M; Harding JJ; Voss MH; Makker V; Ho AL; Razavi P; Iasonos A; Bialer P; Lacouture ME; Teitcher JB; Erinjeri JP; Katabi N; Fury MG; Hyman DM
    Invest New Drugs; 2017 Dec; 35(6):742-750. PubMed ID: 28281183
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    J Mol Diagn; 2017 Mar; 19(2):187-225. PubMed ID: 28185757
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Molecular Biomarkers for the Evaluation of Colorectal Cancer.
    Sepulveda AR; Hamilton SR; Allegra CJ; Grody W; Cushman-Vokoun AM; Funkhouser WK; Kopetz SE; Lieu C; Lindor NM; Minsky BD; Monzon FA; Sargent DJ; Singh VM; Willis J; Clark J; Colasacco C; Rumble RB; Temple-Smolkin R; Ventura CB; Nowak JA
    Am J Clin Pathol; 2017 Mar; 147(3):221-260. PubMed ID: 28165529
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer.
    McRee A; O'Neil BH
    J Oncopathol; 2013 Sep; 1(3):21-29. PubMed ID: 26640695
    [TBL] [Abstract][Full Text] [Related]  

  • 90. RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.
    Cannon TL; Kokon MA; Shafqat S; Deeken JF
    Curr Treat Options Oncol; 2015 Jul; 16(7):33. PubMed ID: 26050230
    [TBL] [Abstract][Full Text] [Related]  

  • 91. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
    Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
    J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Therapeutic targeting of cancers with loss of PTEN function.
    Dillon LM; Miller TW
    Curr Drug Targets; 2014 Jan; 15(1):65-79. PubMed ID: 24387334
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 94. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
    Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S
    Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706
    [TBL] [Abstract][Full Text] [Related]  

  • 95. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis.
    Zhang L; Ma L; Zhou Q
    Int J Colorectal Dis; 2011 Aug; 26(8):1025-33. PubMed ID: 21523374
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis.
    Shen Y; Yang J; Xu Z; Gu DY; Chen JF
    World J Gastroenterol; 2012 Jun; 18(21):2712-8. PubMed ID: 22690082
    [TBL] [Abstract][Full Text] [Related]  

  • 98. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.